TENDYNE HOLDINGS
Tendyne Holdings, Inc. is a clinical stage medical device company focused on the development of minimally invasive therapies for the treatment of mitral regurgitation. Mitral regurgitation is a condition that afflicts hundreds of thousands of individuals worldwide every year. Formed in 2010, their first product concept is a transcatheter mitral valve replacement prosthesis for the treatment of mitral regurgitation. The intent is for the valve to be deployed and secured with no disruption to the native mitral annulus while preserving the sub-valvular apparatus. Placement of the valve is intended to be completed transapically in a simple procedure where the implanting physician is able to re-position, remove, and re-deploy their valve throughout the procedure.
TENDYNE HOLDINGS
Industry:
Biotechnology Clinical Trials Medical Device
Founded:
2010-01-01
Address:
Rockville, Minnesota, United States
Country:
United States
Website Url:
http://www.tendyne.com
Total Employee:
11+
Status:
Closed
Contact:
651-289-5500
Email Addresses:
[email protected]
Total Funding:
37.48 M USD
Technology used in webpage:
SPF Amazon IPv6 Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Microsoft AWS Global Accelerator Comcast Proofpoint
Similar Organizations
Blue Belt Technologies
Blue Belt Technologies is a medical device company that focuses on technology and capabilities of surgical instrumentation.
Nano Precision Medical
Nano Precision Medical develops novel miniaturized subdermal implants
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
Current Advisors List
Current Employees Featured
Founder
Investors List
Apple Tree Partners
Apple Tree Partners investment in Series C - Tendyne Holdings
Official Site Inspections
http://www.tendyne.com
- Host name: aa5dacf57429c8adc.awsglobalaccelerator.com
- IP address: 76.223.40.250
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Tendyne Holdings"
Tendyne Holdings - Crunchbase Company Profile
Tendyne Holdings, Inc. is a clinical stage medical device company focused on the development of minimally invasive therapies for the treatment of mitral regurgitation. Mitral regurgitation is a condition that afflicts hundreds of …See details»
Tendyne Holdings Company Profile 2024: Valuation, Investors ...
Tendyne Holdings General Information Description. Developer of medical device for the treatment of mitral regurgitation. The company engages in the development and commercialization of …See details»
Tendyne Holdings, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Tendyne Holdings, Inc. of Roseville, MN. Get the latest business insights from Dun & Bradstreet.See details»
Tendyne Holdings Company Profile: Overview and Full News Analysis
Tendyne Holdings, located in Minnesota, is a company under Abbott Structural Heart Solutions that specializes in providing innovative solutions for valvular heart disease, congenital heart …See details»
Tendyne Holdings - Contacts, Employees, Board Members
Organization. Tendyne Holdings . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 2. Number of …See details»
Tendyne Holdings - Products, Competitors, Financials, Employees ...
Headquarters Location. 2825 Fairview Avenue North . Saint Paul, Minnesota, 55113, United States. 651-289-5500See details»
Tendyne Holdings | Funding, Valuation & Investors | Finallot
Explore Tendyne Holdings profile on Finallot for insights on its team, products, and industry - Tendyne is a medical device company developing a transcatheter aortic valve implantation …See details»
Tendyne - VentureRadar
Tendyne Holdings, Inc, headquartered in Roseville, MN, is a private medical device company developing a unique Transcatheter Mitral Valve Implant (TMVI). Implanted in a beating heart in …See details»
Tendyne Holdings - Company Profile - Tracxn
Oct 31, 2024 Tendyne Holdings ranks 25th among 108 active competitors. 50 of its competitors are funded while 27 have exited. Overall, Tendyne Holdings and its competitors have raised …See details»
Tendyne - Jean Boulle Group
Tendyne undertook clinical trials in the United States, Great Britain, and Australia in 2015 as part of its multi-centre global feasibility study on the safety and performance of the Tendyne valve. …See details»
Tendyne Holdings - Overview, News & Similar companies
Who is Tendyne Holdings. Tendyne Holdings, Inc., Roseville, Minnesota, USA, is a private clinical stage medical device company developing the Tendyne Bioprosthetic Mitral V alve System for …See details»
Tendyne | Transcatheter Mitral Valve Implantation Valve (TMVI)
Tendyne TMVR provides symptom relief by eliminating MR. 1. Beating heart procedure without the need for cardiopulmonary bypass or rapid pacing; Complete MR elimination in 99% of …See details»
SUMMIT: MV Replacement With Tendyne Shows Promise in …
Oct 30, 2023 Among patients with either severe symptomatic mitral regurgitation (MR) or with severe mitral annular calcification (MAC) who are deemed too high risk for surgery but eligible …See details»
Tendyne Holdings - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Apr 9, 2014: Series C - …See details»
The SUMMIT Tendyne Trial: Changing the Paradigm of MR …
SUMMIT Tendyne Trial Evaluate the safety and effectiveness of the Tendyneâ„¢ Mitral Valve System for the treatment of patients with symptomatic, moderate-to-severe or severe mitral …See details»
Tendyneâ„¢ Mitral Valve Replacement - my-connext.com
Expand the boundaries of MR treatments with Tendyneâ„¢: a repositionable and fully retrievable mitral valve replacement device that eliminates MR, improves quality of life, and reduces Heart …See details»
Approval of Tendyne gives a portfolio of options for TMVI
Mar 10, 2020 Clinical data from the Tendyne global early feasibility study demonstrated excellent procedural safety. A key finding from the study was that 98.9% of Tendyne patients …See details»
Tendyne TM SUMMIT Pivotal Trial Roll-In and MAC Arm Outcomes
Nov 13, 2023 Technical success was 94%, and 97% of patients had Tendyne TM TMVR implanted successfully. 3 pts underwent emergency surgery, and one pt suffered from stroke. …See details»
Abbott's Tendyneâ„¢ Device Receives World's First CE Mark for ...
ABBOTT PARK, Ill., Jan. 30, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its Tendyne â„¢ Transcatheter Mitral Valve Implantation (TMVI) system received CE Mark and is …See details»
Tendyneâ„¢ | Transkatheter-Mitralklappen-Implantation (TMVI)
Tendyneâ„¢ TMVI ist eine bahnbrechende Technologie, welche für Patienten mit symptomatischer, schwerer Mitralinsuffizienz (>3) eine minimalinvasive Behandlungsoption für den …See details»